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Lack of evidence of blood pressure-independent protection by indicated that although antihypertensive agents in gen-
renin-angiotensin system blockade after renal ablation. eral tend to retard this progression, the most consistent
Background. The superiority of renin-angiotensin system and uniform renoprotection is achieved with agents that(RAS) blockade in providing renoprotection has been attrib-
produce a blockade of the renin-angiotensin systemuted to class-specific blood pressure “(BP)-independent” mecha-
(RAS) [9–15]. It has been postulated that the antihyper-nisms. However, the conventional BP measurement methodol-
ogy on which such conclusions are based is inherently limited tensive effects of RAS blockade per se are insufficient
for an accurate assessment of the fluctuating ambient BP pro- to explain its superior renoprotective ability, which has
files. The present studies were undertaken to rigorously exam- therefore been attributed to class-specific, blood pressureine the relationship of renoprotection to the antihypertensive
(BP)-independent effects. Such BP-independent effectseffects of RAS blockade using chronic BP radiotelemetry in
the 5/6 renal ablation model. include: (1) a proportionately greater reduction in glo-
Methods. Rats with 5/6 renal ablation received either no treat- merular capillary pressure (PGC) for any given reduction
ment, the angiotensin-converting enzyme inhibitor benazepril in systemic BP as a consequence of the preferential effer-
at a dose of 25, 50, and 100 mg/L; or the angiotensin receptor
ent arteriolar dilation produced by RAS blockade [5, 9,antagonist losartan at a dose of 50, 120, and 180 mg/L of
10, 12, 16]; and/or (2) a blockade of specific angiotensindrinking H2O; and were followed for seven weeks.
Results. Glomerulosclerosis (GS) at sacrifice (approximately II-mediated pathogenetic effects on glomerular cells that
7 weeks) demonstrated a close correlation with the average favor the development of progressive GS. These effects,
systolic BP in untreated (r 5 0.76, N 5 20), benazepril-treated mediated through the activation of the angiotensin II(r 5 0.80, N 5 33), losartan-treated (r 5 0.83, N 5 32), or
type 1 receptor (AT1) [17, 18], include glomerular hyper-all animals combined (r 5 0.81, N 5 85, P , 0.0001 for all
trophy, an increased expression of growth factors suchcorrelations). The slope of the relationship between GS and
BP (percentage of increase in GS/mm Hg increase in BP) in as transforming growth factor-b and platelet-derived
untreated rats (0.7 6 0.14) was not significantly altered by growth factor and an increased matrix accumulation with
either benazepril (0.96 6 0.13) or losartan (0.60 6 0.08), indicat-
eventual GS [3, 18–23].ing that RAS blockade, by either agent, resulted in renoprotec-
These widely accepted conclusions as to the contribu-tion that was proportionate to the achieved BP reductions.
Conclusions. These data demonstrate that RAS blockade tion and importance of BP-independent pathways in the
provides renoprotection in the rat remnant kidney model of renoprotection provided by RAS blockade are, however,
progressive GS, primarily through “BP-dependent” and not critically dependent on an accurate and adequate assess-“BP-independent” mechanisms.
ment of the ambient BP profiles and glomerular pressure
burden, and the assumption that conventional BP mea-
surements are sufficient to separate the “BP-dependent”
The mechanisms responsible for the progressive na-
and “BP-independent” effects of therapeutic interventions.ture of chronic renal disease remain the subject of intense
However, BP characteristically exhibits rapid, spontaneous,investigation and debate [1–8]. Data obtained in several
and large BP fluctuations in conscious, unrestrained ratsexperimental models and in human renal disease have
(and other species), particularly when hypertension is
present [24–28]. Such BP lability makes it extremely un-
likely that the conventional methodology for BP measure-Key words: hypertension, glomerulosclerosis, AT1 receptor antagonist,
angiotensin-converting enzyme inhibitor, progressive renal disease. ments used in such investigations can assess the overall
pressure burden with sufficient accuracy to allow defini-Received for publication June 11, 1999
tive conclusions. Therefore, the present studies were un-and in revised form October 20, 1999
Accepted for publication November 2, 1999 dertaken to rigorously examine the dose-response rela-
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effects of RAS blockade using BP radiotelemetry in the sure. A femoral vein was cannulated with PE-50 tubing,
and a priming dose of inulin in 150 mmol/L NaCl wasremnant kidney model of 5/6 renal ablation, in which
conventional BP measurements have indicated the protec- administered, followed by a continuous maintenance in-
fusion of 150 mmol/L NaCl containing inulin at 0.055tion by both angiotensin-converting enzyme (ACE) inhib-
itors and AT1 receptor antagonists to be “BP indepen- mL/min to maintain the plasma concentration of inulin at
approximately 50 mg/dL, and for replacement of surgicaldent” [3, 9, 12, 19].
and ongoing fluid losses. The left ureter was then cannu-
lated with polyethylene tubing for the collection of urine
METHODS
samples. A 1.0 mm R series flow probe (Transonic Sys-
Studies were conducted in male Sprague-Dawley rats tems, Inc., Ithaca, NY, USA) was placed around the left
(body weight 225 to 300 g) that were fed a standard renal artery for measurement of renal blood flow (RBF)
(24%) protein diet (Purina, St. Louis, MO, USA) and by a flowmeter (Transonic Systems, Inc.), as described
synchronized to a 12:12-hour light (6:00 to 18:00 h) and previously [27–31]. At the conclusion of the surgery, a
dark (18:00 to 6:00 h) cycle. All rats received food 150 mmol/L NaCl bolus equal to 1% of body weight was
and water ad libitum throughout the study. administered. Two 20-minute clearances of inulin were
obtained. Blood samples were obtained at the midpoint
Radiotelemetry
of each urine collection. At the conclusion of these stud-
The rats were anesthetized with sodium pentobarbital ies, the rats were killed, and the kidneys were harvested
(45 mg/kg intraperitoneally), subjected to ,5/6 renal for morphological studies.
ablation (right nephrectomy and ligation of all but one
posterior extrarenal branch of the left renal artery), and Morphology and morphometrics
prepared for telemetric monitoring of BP (Data Sciences Transverse sections of the kidney through the papilla
International, St. Paul, MN, USA) at the time of the were fixed in situ by perfusion for five minutes at the
renal ablation surgery as previously described [27–31]. measured BP with 1.25% glutaraldehyde in 0.1 mol/L
Each rat had a BP sensor inserted intraperitoneally. The cacodylate buffer. Sections were cut at a thickness of 2 mm
sensor’s catheter was inserted into the aorta below the and stained with hematoxylin and eosin and periodic
level of the renal arteries, and the radio frequency trans- acid-Schiff. Sections were evaluated systemically in each
mitter was fixed to the peritoneum. The rats were housed kidney for glomerular injury (segmental sclerosis and/or
individually in plastic cages that were placed on top of necrosis) in a blinded fashion by standard morphologic
the receiver. The signals from the pressure sensor were methods [4, 27–31]. At least 100 glomeruli in each animal
converted, temperature compensated, and sent via the were evaluated, and the severity of GS was expressed
radio frequency transmitter to the telemetry receiver. as the percentage of glomeruli exhibiting such injury.
The receiver was connected to a BCM-100 consolidation We have previously shown that this method yields results
matrix that transmitted the information to the Lab Pro that are essentially identical to an alternative method
data acquisition system. Systolic BP in each animal was that uses a morphometric scoring method to estimate GS
recorded at 10-minute intervals throughout the course [28, 32] in terms of correlation with proteinuria and/or
of approximately seven weeks, with each reading being BP parameters. Glomerular volume (VG) was measured
the average value obtained during a 10-second sampling by area perimeter analysis (Bioquant System IV soft-
period. Tail vein blood samples were obtained at three ware; R&M Biometrics, Inc., Nashville, TN, USA). The
days for the measurement of serum creatinine as an cross-sectional area (AG) of 75 consecutive glomerular
index of the degree of renal mass reduction [29]. At profiles contained in one kidney section for each animal
approximately seven days, the rats were randomly as- was measured using a digitizing pad as described pre-
signed to the untreated group or received one of three viously [27–31]. The mean VG was then calculated from
doses of the ACE inhibitor benazepril (25, 50, 100 mg/L) the respective mean AG as VG 5 b/k (AG3/2), where b 5
or the AT1 receptor antagonist losartan (50, 120, 180 mg/L) 1.38 is the size distribution coefficient and k 5 1.1 is the
of drinking water. After seven weeks, 24-hour urine col- shape coefficient for glomeruli idealized as spheres [33].
lections were obtained to measure the protein excretion.
Analyses, calculations, and statisticsThe rats were then anesthetized with intravenous sodium
pentobarbital (40 mg/kg). A tracheostomy was per- Urinary protein was measured by the quantitative sul-
formed using polyethylene (PE-200) tubing, and the rats fosalicylic acid method, with human serum albumin serv-
were surgically prepared for clearance studies as de- ing as the standard. Creatinine was measured using a
scribed previously [27–31]. In brief, a carotid artery was creatinine analyzer (Beckman Instruments, Inc., Fuller-
cannulated with PE-50 tubing and connected to a Windo- ton, CA, USA) [29–31]. Inulin in urine and plasma fil-
graf (model 40-8474; Gould Inc., Glen Burnie, MD, trates was determined spectrophotometrically by the di-
phenylamine method as described previously [27–31].USA) for continuous recording of the mean arterial pres-
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Table 1. Renal function data after RAS blockade
Initial 3 days Final
Body weight SCr 24 h Protein SCr Body weight RBF GFR
N g mg/dL mg/24 h mg/dL g mL/min/kg mL/min/kg
Untreated 20 25765 0.3360.01 3.560.4 0.8260.3 426610 24.262.3 2.560.3
Benazepril 25 10 26264 0.3560.02 2.760.2 0.8660.06 427614 25.263.3 2.660.3
Benazepril 50 12 25464 0.3860.03 3.360.5 0.8360.05 45069 35.562.6ab 3.260.3
Benazepril 100 11 24867 0.2960.04 2.860.3 0.8060.04 43269 36.062.7ab 3.860.3a
Losartan 50 9 25167 0.3060.02 3.060.7 0.8860.06 432612 30.463.5 2.860.3
Losartan 120 12 25864 0.3260.03 3.760.7 0.8360.04 428613 34.262.6a 3.760.3a
Losartan 180 11 24766 0.3260.02 4.260.6 0.8460.04 40867 41.362.3ab 4.460.5abc
SCr is serum creatinine.
aP , 0.05 vs. Untreated
bP , 0.05 vs. Benazepril 25
cP , 0.05 vs. Losartan 50
The glomerular filtration rate (GFR) was calculated us- highest dose of losartan (180 mg/L). The differences in
the overall “pressure load” between the seven groupsing standard formulae. Linear regression analysis was
used to calculate the slopes and intercepts of the relation- are summarized and illustrated by a comparison of the
average systolic BP during the first week before the initi-ship between BP and GS in each group. Statistical analy-
sis was performed using analysis of variance followed by ation of treatment and during the following approxi-
mately six weeks (Fig. 3). The average BP during theStudent-Newman-Keuls test or by Kruskal-Wallis non-
parametric analysis of variance followed by Dunn’s mul- final six weeks was modestly but significantly higher in
the untreated control rats as compared with their respec-tiple comparison test as appropriate [34]. Analysis of
covariance was used to compare the slopes and intercepts tive first-week values. By contrast, the average systolic
BP of all treated animals during the final six weeks wasbetween the groups using the Minitab Software package
significantly lower than their respective average systolic(Minitab, Inc., PA, USA) [34]. A P value of , 0.05 was
BP during the first week before the initiation of treat-considered statistically significant. All results are ex-
ment, when the paired t-test was used for comparisonpressed as mean 6 SE.
within each group. However, because of the substantial
variability of the average individual systolic BP values
RESULTS within each of the subgroups receiving either the lowest
Table 1 shows that the initial body weight, serum creat- dose of benazepril (25 mg/L) or the two lower doses
inine, and 24-hour urine protein excretion for the seven of losartan (50 and 120 mg/L), these values were not
groups were not significantly different from each other. statistically different from that of the untreated control
Similarly, the serum creatinine at three days was not rats. By contrast, the average posttreatment systolic BP
significantly different between the groups, indicating of the groups receiving the two higher doses of benaze-
comparable renal mass reduction in all groups. The final pril (50 and 100 mg/L) and the group receiving the high-
body weight at seven weeks was also not significantly est dose of losartan (180 mg/L) was comparably and
different between the five groups. significantly reduced as compared with the untreated
Figure 1 illustrates the systolic BP recordings from control group (P , 0.01).
individual rats that were untreated, received benazepril The protein excretion rate (mg/24 h) at the end of
50 mg/L, or received losartan 180 mg/L, and it shows seven weeks and the percentage of glomeruli exhibiting
the persistence of significant BP lability despite a marked GS in the remnant kidneys of these seven groups are
reduction in systolic BP. Figure 2 illustrates the course presented in Figure 4. Graded reductions in proteinuria
of weekly averages of systolic BP after ,5/6 renal abla- and GS were seen in the benazepril- and losartan-treated
tion in untreated animals and the three groups each groups, which paralleled the reductions in their respec-
treated with the different dosages of the ACE inhibitor tive BP as compared with the untreated rats. However,
benazepril or the AT1 receptor antagonist losartan. The as was the case for the average post-treatment systolic
average BP during the first seven days after renal abla- BP values, statistical significance was only achieved for
tion and before the initiation of antihypertensive therapy reductions in proteinuria and GS in the groups receiving
was comparable in the seven groups. An initiation of the two higher doses of benazepril (50 and 100 mg/L)
RAS blockade resulted in BP reductions in all six groups. and the highest dose of losartan (180 mg/L). RBF and
The BP reduction was the most pronounced for the GFR measurements obtained in these rats before sacri-
fice similarly indicated better preservation of renal func-groups receiving 50 or 100 mg/L of benazepril and the
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Fig. 1. Course of systolic blood pressure
(BP) recorded every 10 minutes for approxi-
mately seven weeks in a rat with ,5/6 renal
ablation from (A) an untreated control rat,
(B) a rat receiving 50 mg/L in drinking water
of benazepril, and (C ) a rat receiving 180 mg/L
in drinking water of losartan, showing the per-
sistence of significant BP lability despite a
marked reduction in systolic BP. The initia-
tion of therapy is indicated by the arrows (#).
tion in these same groups of rats receiving the higher 0.76, P , 0.001), benazepril-treated rats (r 5 0.80, P ,
0.001), or the losartan-treated rats (r 5 0.83, P , 0.001).doses of benazepril or losartan (Table 1).
Figure 5A shows the correlation of average systolic Figure 5B shows the separately calculated regression
lines for the untreated, benazepril-, or losartan-treatedBP and GS in all of the individual rats in the study. An
excellent direct correlation was observed (r 5 0.81, P , rats and shows that the slopes and the intercepts of the
relationship between BP and GS in the benazepril- and0.0001). Similar strong correlations were observed be-
tween the average systolic BP and GS when data were losartan-treated groups were not significantly different
from untreated rats.separately analyzed for the untreated control rats (r 5
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Fig. 1. (Continued).
proteinuria was less strong (untreated, r 5 0.67; benaze-
pril treated, r 5 0.58; losartan treated, r 5 0.77) or for
all animals combined (r 5 0.72).
Figure 6 shows the effects of RAS blockade on rem-
nant kidney and glomerular growth. The remnant kidney
weight factored for body weight was not significantly
different between the treated groups or in comparison
to untreated rats. Similarly, glomerular volume was not
significantly different between the treated groups or as
compared with the untreated group. The correlations
between glomerular volume and GS were not significant
within the individual groups (untreated controls, r 5
0.36; benazepril, r 5 0.11; and losartan, r 5 0.21, P .
0.05 for all correlations). However, when the groupsFig. 2. Course of systolic BP (24 hour averages) over approximately
were combined, a significant but weak correlation wasseven weeks in the seven groups. All rats underwent ,5/6 renal ablation
(right nephrectomy 1 infarction of ,2/3 of the left kidney). After observed (r 5 0.29, P , 0.01).
seven days, the rats were left untreated (h; N 5 20) or received either
benazepril at a dose of 25 (r; N 5 10), 50 (d; N 5 12), or 100 (solid
star; N 5 11) mg/L of drinking H2O, or losartan at a dose of 50 (open DISCUSSIONdiamond; N 5 9), 120 (s; N 5 12), or 180 (open star; N 5 20) mg/L
of drinking water. BP was radiotelemetrically recorded continuously at Numerous previous studies have compared the salu-
10-minute intervals.
tary effects of RAS blockade with that of other antihy-
pertensive regimens on the progression of both experi-
mental and clinical renal disease [5, 9–15]. With few
exceptions, such studies have concluded that RAS block-An excellent correlation was also observed between
histologic glomerular injury (% GS) and its functional ade is more consistently effective in providing renopro-
tection as compared with other therapeutic interven-correlate, proteinuria, whether the analysis was per-
formed for all animals combined (r 5 0.85) or whether tions, but the responsible mechanisms remain the subject
of controversy [2, 3, 5, 6, 9–12, 16, 18–23]. Although suchindividual groups were separately analyzed (untreated,
r 5 0.73; benazepril treated, r 5 0.87; or losartan treated, RAS blockade-conferred protection has almost uni-
formly been associated with significant BP reductions,r 5 0.81). However, the correlation between BP and
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Fig. 3. Overall average BP during the first
seven days (A) and during the subsequent ap-
proximately six weeks (B) in 5/6 renal ablated
rats that, after the seventh day, were: left un-
treated (h); received benazepril at 25, 50, or
100 mg/L of drinking H2O (j); or received
losartan at 50, 120, or 180 mg/L of drinking
water ( ). BP was radiotelemetrically re-
corded continuously at 10-minute intervals.
*P , 0.001 compared with untreated controls;
*P , 0.05 maximum compared to the respec-
tive average systolic BP of the same group
during the first week.
Fig. 4. Proteinuria (A) and percentage glo-
merulosclerosis (B) at the end of approxi-
mately seven weeks in the rats with ,5/6 renal
ablation that were: left untreated (h); re-
ceived benazepril at 25, 50, or 100 mg/L (j);
or received losartan at 50, 120, or 180 mg/L
( ) of drinking water after the first week.
*P , 0.01 maximum compared with untreated
controls.
nevertheless, the superiority of RAS blockade has been adequate to ensure “equivalent BP control,” a critical
prerequisite for the valid interpretation of the observedattributed to “BP-independent” mechanisms, as equiva-
lent BP reductions achieved with other antihypertensive differences between antihypertensive regimens. The ne-
cessity of an accurate assessment of the ambient BPclasses have often failed to provide comparable protec-
tion. Such evidence, however, is less than definitive. Con- profiles and the pressure burden on the kidneys is dem-
onstrated by the exceedingly close linear relationshipventional BP measurements are obtained at intervals
ranging from one to several weeks, when, in fact, BP between the overall average systolic BP and GS when
chronic BP radiotelemetry is used to measure BP contin-displays substantial moment-to-moment lability [24–31].
This fundamental time-dependent BP variability, which uously in untreated individual rats after ,5/6 renal abla-
tion, consistent with the hypertensive pathogenesis ofpersists during treatment with antihypertensive agents
[28, 30, 31], renders conventional BP measurements in- GS in this model [27]. The alternative interpretation—
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Fig. 5. (A) Correlation of the percentage of glomeruli with sclerosis at approximately seven weeks in individual rats with 5/6 renal ablation and
their average systolic BP during the final six weeks (the mean of all approximately 6000 BP readings in each rat). After the first seven days, the
rats had received: no treatment (h; N 5 20); benazepril at 25 (r; N 5 10), 50 (d; N 5 12), or 100 (solid star; N 5 11) mg/L; or losartan at 50
(open diamond; N 5 9), 120 (s; N 5 12), or 180 (open star; N 5 11) mg/L in drinking water. (B) Linear regression analysis of the slopes of the
relationship between the average BP during the final six weeks and % GS for all rats combined and separately for the untreated (h; N 5 20),
benazepril-treated (d; N 5 33), and losartan-treated (s; N 5 32) rats. Untreated (N 5 20): r 5 0.76, slope 0.71 6 0.14, x intercept 136 mm Hg;
benazepril (N 5 37): r 5 0.80, slope 0.96 6 0.14, x intercept 125 mm Hg; losartan (N 5 32): r 5 0.83, slope 0.60 6 0.08, intercept 124 mm Hg.
The slopes and intercepts for the individual groups were not significantly different from each other or from the combined slope and intercept for
all animals in the study (N 5 85, r 5 0.81, slope 0.72 6 0.05, x intercept 123.7 mm Hg).
that GS is the primary determinant and hypertension is variability in GS in individual animals. Although we did
not directly compare other antihypertensive regimens tothe dependent variable [35]—is rendered less tenable
because hypertension antedates the development of GS RAS blockade in the present study, the present results
are consistent with the results obtained in an earlier studyin the model [27]. Moreover, if such an interpretation
was valid, a progressive increase in the severity of hyper- in which a single-dose regimen of the ACE inhibitor
enalapril was compared with two different dosages of atension would be expected in untreated animals after
the third week with worsening GS, and such is not seen combined triple-therapy regimen of hydralazine, hydro-
chlorothiazide, and reserpine [28]. Renoprotection wasin the majority of untreated rats over the observed time
course [27]. found to be proportional to the achieved BP reduction
with all antihypertensive regimens, and the superior re-Given this close linear relationship between BP and
GS, the impact of an antihypertensive agent on the slope noprotection provided by enalapril could be accounted
for by its superior antihypertensive efficacy. However,of this relationship (increase in percentage GS/mm Hg
increase in BP) may provide a more valid method to because the single dose (50 mg/L) of enalapril used, in
that as well as another study [30], was very effective inseparate the agent’s “BP-dependent” and “BP-indepen-
dent” effects on GS [28, 30, 31]. If a given antihyperten- reducing BP (,135 to 140 mm Hg), the relationship
between BP and GS after RAS blockade could only besive agent reduces both BP and GS, but does not signifi-
cantly alter the slope of the relationship between BP examined within a narrow BP range. By contrast, the pres-
ent studies show that the protection by RAS blockadeand GS from that observed in untreated animals, the
glomeruloprotection can be ascribed primarily to its BP- is BP dependent across the entire BP range in this model.
The antihypertensive effectiveness of RAS blockadedependent (antihypertensive) effects [28]. A significant
contribution of “BP-independent” mechanisms to the in the 5/6 renal ablation model suggests that hyperten-
sion in this model may be largely angiotensin II depen-glomeruloprotection by a therapeutic intervention would
be expected to reduce the slope and/or to shift it to the dent. Such an interpretation regarding the pathogenesis
of hypertension in the 5/6 renal ablation model is consis-right. Such an effect was not observed with any of the
agents or dosages used for RAS blockade. Nevertheless, tent with the well-characterized effects of both systemic
and/or locally generated angiotensin II in the develop-GS at sacrifice in individual animals showed an excellent
correlation with their average systolic BP within each ment and maintenance of hypertension [16]. Of note,
although the mean BP data of the various subgroups isgroup treated with either the ACE inhibitor or the AT1
receptor antagonist. These data indicate that GS in both consistent with a dose-dependent antihypertensive effect
of both ACE inhibitors and AT1 receptor blockade, suchuntreated and treated animals with remnant kidneys is
primarily BP dependent, with differences in the overall an interpretation is in some sense misleading. An exami-
nation of the individual animal data demonstrates sig-BP burden possibly accounting for 60 to 65% of the
Bidani et al: RAS blockade and GS1658
Fig. 6. Kidney weight and glomerular vol-
ume at the end of approximately seven weeks
in the rats with ,5/6 renal ablation that were:
left untreated (h); received benazepril 25, 50,
or 100 mg/L (j); or received losartan 50, 120,
or 180 mg/L ( ) of drinking water after the
first week. There were no significant differ-
ences between the groups.
nificant heterogeneity within the subgroups receiving the sodic or sustained) from being transmitted to the glomer-
ular capillaries [38–40]. This preglomerular autoregula-lower doses of each agent. These data indicate that, while
the lower dose of either agent is sufficient to produce tory vasoconstriction is dependent on calcium entry
through voltage-gated calcium channels and is conse-normotension in a certain proportion of rats with 5/6
ablation, an increase in dosage results in an increase in quently impaired by calcium channel blockers in animals
with intact kidneys [40–42]. The observation that thethe number of individual rats that achieve normotension
within a subgroup. However, a further increase in the dihydropyridine calcium channel blockers cause an addi-
tional impairment of renal autoregulation in this modeldose, as for instance of benazepril from 50 to 100 mg/L
in drinking water, did not result in further BP reductions and also have a predictable adverse effect on the rela-
tionship between BP and GS emphasizes the importanceand, of significance, did not provide greater renoprotec-
tion. Thus, the present data do not provide support for of the preglomerular resistance as a major determinant
of the susceptibility to GS for any given BP elevationthe concept that dosages of RAS blockade higher than
that required to produce normotension may provide ad- [30, 31]. ACE inhibitors, by contrast, do not alter the
impaired autoregulatory responses of the preglomerularditional “BP-independent” renoprotection [11, 18]. The
significant individual variability within a subgroup fur- vasculature in this model [30], but are thought to exert
their superior renoprotective effects through blockadether emphasizes the limitations of group comparisons,
and suggests that additional individual animal data anal- of the tonic vasoconstrictor effects of angiotensin II on
the postglomerular efferent arteriole [5, 9, 10, 12, 16].yses as performed in the present study may provide truer
insights into the antihypertensive effects of RAS block- Although the efferent arteriole does not participate in
autoregulation [38, 39, 43], it is, nevertheless, an impor-ade as well as the relationship between BP and GS in
this model. tant determinant of the ambient PGC [16, 43]. Thus, con-
comitant relative efferent arteriolar dilation by RASGlomerulosclerosis is expected and postulated to be a
consequence of an increase in local glomerular pressures, blockade would be postulated to result in a dispropor-
tionate reduction in PGC for any given reduction in sys-rather than systemic BP per se; therefore, the close corre-
lation observed between BP and GS indicates that glo- temic BP [5, 9, 10, 12, 16]. Micropuncture studies in rats
with 5/6 renal ablation, comparing RAS blockade tomerular capillary pressure (PGC) profiles parallel the
fluctuating systemic pressures in individual animals with other antihypertensives, are consistent with such a postu-
late [5, 9, 10, 12, 19]. However, the results of the present5/6 renal ablation. Such an interpretation is consistent
with studies that have demonstrated that the renal auto- study do not provide support for a significant contribu-
tion of such a mechanism to the overall glomeruloprotec-regulatory mechanisms are impaired in rats with 5/6 abla-
tion [36, 37]. Normally, the autoregulatory vasoconstric- tion provided by chronic RAS blockade. A potential
explanation for this seeming dissociation between thetor responses of the preglomerular vasculature, most
prominently the afferent arteriole, provide the primary results predicted by the micropuncture studies and the
present data may stem from the inherent limitations ofprotection against increases in systemic pressure (epi-
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the micropuncture methodology. PGC measurements are, to be a mediator of the preferential efferent arteriolar
dilation and PGC reduction observed with ACE inhibitorsby necessity, obtained at a single time point in anesthe-
tized rats, and anesthesia activates both the neurohormo- [18, 56, 57]. Conversely, chronic ACE inhibition may
not eliminate the continued production of angiotensinnal systems and the RAS [44, 45], which can indepen-
dently alter segmental vascular resistances and magnify II through ACE-independent pathways, albeit at lower
but still potentially pathogenic levels [18, 55]. Therefore,the contribution of efferent arteriolar resistance to the
observed PGC, given the potential for enhanced renin it has been suggested that the more distal blockade of
RAS by AT1 receptor antagonist may be more effectiverelease in this model [46]. Additionally, isolated PGC mea-
surements are likely to have limitations similar to that in blocking the AT1 receptor-mediated adverse cellular
effects of angiotensin II as compared with ACE inhibi-of isolated BP measurements [27, 28, 30].
“Blood pressure-independent” protection by RAS tors [18, 55]. It has also been suggested that AT1 receptor
antagonists may, in fact, enhance AT2 receptor activationblockade is also postulated to occur via a blockade of
the nonhemodynamic adverse effects of angiotensin II by angiotensin II, which has the potential for additional
beneficial cellular effects [18, 55, 58]. No differences wereon glomerular growth, mesangial proliferation, increased
expression of transforming growth factor-b and platelet- observed in the present study between ACE inhibition
and AT1 receptor antagonism, suggesting that the describedderived growth factor, increased production and accumu-
lation of extracellular matrix, and eventual GS [18–23]. differences between these two methods of RAS blockade
may not play a significant role during chronic therapy,Of these potential pathogenetic mechanisms, only the
issue of glomerular growth is addressed directly by the consistent with previous results in this model [54].
Thus, in summary, the present studies show that atpresent data, which show that differences in GS between
individual animals treated with RAS blockade are not least in the renal ablation model, renoprotection by RAS
blockade is “BP dependent.” No evidence of “BP-inde-explained by differences in glomerular growth. Although
the cellular and molecular basis for the structural com- pendent” protection was observed, despite the extensive
documentation of the potential “BP-independent” ad-pensatory hypertrophy response remains controversial
at present, the predominant stimulus seems to be renal verse effects of angiotensin II in the pathogenesis of GS
in this model. These data, however, do not exclude themass reduction per se. For instance, compared with con-
trols, equivalent increases in glomerular volume are ob- unexamined possibility that dose-dependent and “BP-
independent” beneficial effects of RAS blockade mayserved after 5/6 renal mass reduction regardless of whether
the rats are hypertensive with increased RAS activity be observed after substantially longer follow-up in these
rats. Similarly, it is possible that in states such as diabetes,(the infarction model) or normotensive with relative
RAS suppression (the surgical excision model) [29, 47]. where hypertension may be less angiotensin II depen-
dent or the mechanisms of renal injury may be less “BPSuch an interpretation is also consistent with the variable
effects of RAS blockade on glomerular hypertrophy seen dependent” [59], the “BP-independent” pathways asso-
ciated with RAS blockade may play a more significantin this model [19, 48, 49]. Although the present data do
not address the potential individual contributions of the role [13, 14, 18, 20, 23, 59]. Such models therefore may
be more appropriate than the 5/6 ablation model for theother local cellular pathways that mediate the eventual
development of GS, they strongly suggest that local baro- investigation of “BP-independent” effects of antihyper-
tensive agents. Nevertheless, it is of note that the demon-trauma and/or the glomerular capillary stretch conse-
quent to the increased PGC, rather than angiotensin II stration of “BP-independent” beneficial effects of RAS
blockade in these disease states has also to date beenper se, may be the primary initiating mechanism for these
pathways [50, 51]. Alternatively, such deleterious cellular based on only conventional BP measurements.
effects of angiotensin II may require the presence of
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